{"name":"HuniLife Biotechnology, Inc.","slug":"hunilife-biotechnology-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Lenalidomide and Dexamethasone","genericName":"Lenalidomide and Dexamethasone","slug":"lenalidomide-and-dexamethasone","indication":"Multiple myeloma (newly diagnosed or relapsed/refractory)","status":"phase_3"}]}],"pipeline":[{"name":"Lenalidomide and Dexamethasone","genericName":"Lenalidomide and Dexamethasone","slug":"lenalidomide-and-dexamethasone","phase":"phase_3","mechanism":"Lenalidomide enhances immune cell activity and has anti-angiogenic properties, while dexamethasone provides anti-inflammatory and immunosuppressive effects to manage multiple myeloma.","indications":["Multiple myeloma (newly diagnosed or relapsed/refractory)","Light chain myeloma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxNYVZGb1d4SlV6bHhTQ0RSVURidk9lekxZR0JyZlM1OEFCcmNBcnpaNGZCZzdybERwZFNjb2VSSjJmWXJpdUMwbWMxZW93ZXY0SV8wUDRBSVRaaFRxeFpPNXFCZ3JqQUpwbEtWdFNEY2lPYURISVF2QmV4aG8zdmw0dlpxV0RFT3VnV29fRmdkdDd3WkVrM1VJaU5rb0J3aHdGbkhGeE0yRFM4clBOQWxGT0JaTFcxS3VlVHZzNHU1YjlhQlEtcG1OUjlzdEp1QjU5RlNBeXNlcHZJLVl6SVBONkdkTQ?oc=5","date":"2024-11-13","type":"pipeline","source":"PR Newswire","summary":"75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - PR Newswire","headline":"75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPbkdobWFuXzdITklNSHFEYVkxdXVRVjc1aWtJRmlSR3lXYzNfekVfWTkyM0ppaTAzZTVSQXRnNnFwOURqLUZzWW13SG1xMlY2QVZ1dk5UamJfYkhaVkVEUXp4YkMwcHpRazBsUTMwV1QwUVZkcVhQak1WRnlKQXRlODBoQk9SclFySGVoTUVZSGdNUmVIQldmZTZ1NjZXR010NmhHYmpqSUZvVU5KdmJ2Zk9TUVhkNzJjWDk2MWNWRklCQ0pS?oc=5","date":"2024-09-10","type":"pipeline","source":"PR Newswire","summary":"BTK Inhibitors Market to Observe Stunning Growth by 2034 | DelveInsight - PR Newswire","headline":"BTK Inhibitors Market to Observe Stunning Growth by 2034 | DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}